Compare Summit Therapeutics Inc (SMMT) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Stanley Black & Decker, Inc. — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while Stanley Black & Decker, Inc. trades at $87.62 (market cap $13.60B). The key difference: Stanley Black & Decker, Inc. is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays a 3.79% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | SWK | |
|---|---|---|
Market Cap | $10.48B | $13.60B |
Sector | Health | — |
52-Week High | $29.32 | $94.12 |
52-Week Low | $13.05 | $62.12 |
Enterprise Value | $9.90B | $19.77B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Stanley Black & Decker (SWK) trades at $88.19, down 2.2% on the day, with a neutral technical outlook and mixed analyst sentiment. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.80 surpassing the $0.59 estimate. Fundamentals reveal a P/E of 35.86 and net income margin of 2.44%, while cash flow trends indicate stable operations. Recent news highlights strength in aerospace and automotive segments but notes weak Tools & Outdoor demand.
SWK offers value with a P/S of 0.87 and dividend yield appeal, but high debt and margin pressures pose risks. The consensus price target is $83.00, with 43% of analysts rating it a buy. Earnings growth and debt reduction are key catalysts, though sector headwinds and economic sensitivity remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
